Tropical Journal of Natural Product Research

Available online at https://www.tjnpr.org *Original Research Article*

Drug-Piperaceae Herb Interaction Potency Through Analgesic, Anxiolytic, and Anti-Inflammatory Activity Studies

Fransiska M. Christianty^{1*}, Arista S. Dewi², Fitrotun Khasanah², Diana Holidah¹, Ika P. Dewi¹, Fifteen A. Fajrin¹

¹Preclinical Pharmacology Research Group, Pharmacology and Animal Experimental Laboratory, Faculty of Pharmacy, University of Jember, Jember 68121, East Java, Indonesia ²Undergraduate students, Faculty of Pharmacy, University of Jember, Jember 68121, East Java, Indonesia

ARTICLE INFO ABSTRACT

Article history: Received 16 November 2023 Revised 03 April 2023 Accepted 06 April 2024 Published online 01 May 2024

Copyright: © 2024 Christianty *et al*. This is an openaccess article distributed under the terms of the [Creative Commons](https://creativecommons.org/licenses/by/4.0/) Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Integrative therapy by combining conventional with herbal medicines is one of the choices for the community. However, there are opportunities for potential drug-herb interactions. Piperine, the primary alkaloid in the Piperaceae family, has been shown to change the pharmacokinetic profile of drugs and influence drug pharmacodynamics. This study aimed to determine the potential interactions between the combination of Piperaceae herb extract and conventional drugs based on their pharmacological activity *in vivo*. Black and Javanese long pepper extracts were prepared using the maceration method in ethanol. Then, the piperine level was determined using the TLCdensitometric method. Potential interactions were investigated through *in vivo* analgesic, anxiolytic, and anti-inflammatory activity studies. Piperine content in black and Javanese long pepper extract was 20.46% and 15.65%, respectively. Conventional drugs consumed with piperine or Piperaceae herbal extracts showed an increase in the latency time of mice on a hot-cold plate but a decrease in mice's survival time on the rotarod and oedema volume compared to single drug administration at various times. All combined treatments also enhance the percentage of analgesic (21.73% to 25.60%), anxiolytic (65% to $\geq 80\%$), and inflammation inhibitory (14.81% to ≥51.85%) activities of drugs. It concluded that piperine in black pepper or Javanese long pepper extracts has the potency to interact with drugs, especially with diclofenac sodium, alprazolam, and dexamethasone, based on the enhancement of their activity. Thus, further research is needed to determine its toxicity and pharmacokinetic profile to ensure the safety of these drug interactions.

*Keywords***:** Piperaceae, piperine, drug-herb interaction

Introduction

The rapid development and trend of natural-based medicine make integrative therapy, which combines conventional and herbal medicines, one of the choices for the community. However, there are opportunities for drug-herb interactions that need to be considered because they can be beneficial, detrimental, or even fatal.¹ Previous research found that 13.2% of people in Indonesia consumed combinations of herbal medicines with conventional medicines, with some of them having beneficial interactions (13.5%), harmful (18.9%), and no interaction (67.6%) .²

This study focused on the interactions with Piperaceae herbs. This family is a natural vegetative plant with several species identified and spread across Meru Betiri Jember National Park.³ The Piper genus, one of the Piperaceae family, is often used as spices, food mixtures, and traditional medicine with emollient, antirheumatic, diuretic, stimulant, abortive, anti-inflammatory, antibacterial, and antifungal properties.⁴ The fruit contains piperine alkaloids known to have many properties, including anti-inflammatory and anti-arthritis agents, hypoallergenic, cardiovascular protection, anti-hyperlipidemia, anti-obesity, neuroprotective, and antiparkinson effects.⁵

*****Corresponding author. E mail: fransiska.farmasi@unej.ac.id Tel: +6281336690096

Citation: Christianty FM, Dewi AS, Khasanah F, Holidah D, Dewi IP, Fajrin FA. Drug-Piperaceae Herb Interaction Potency Through Analgesic, Anxiolytic, and Anti-Inflammatory Activity Studies. Trop J Nat Prod Res. 2024; 8(4):6781-6786. [https://doi.org/10.26538/tjnpr/v8i4.6](https://doi.org/10.26538/tjnpr/v8i4.)

Official Journal of Natural Product Research Group, Faculty of Pharmacy, University of Benin, Benin City, Nigeria

Previous studies have shown that piperine is a bioenhancer that can increase drug levels in the blood.⁶ Piperine inhibits the activity of pglycoprotein and drug-metabolising enzymes. It can increase drug absorption and bioavailability.⁷ Other studies have shown that piperine can improve the pharmacokinetic profile of low bioavailability drugs, such as propranolol⁸ and curcumin.⁹ Treatment with piperine can also change the pharmacokinetic profile of fexofenadine¹⁰, almotriptan¹¹, and other drug substrates of p-glycoprotein and cytochrome P450 enzymes. Piperine, a significant component of the genus Piper, is implicated in drug-herb interactions. So far, the existing research has only studied the interaction between piperine and drugs, while studies of Piperaceae herbs, when combined with drugs, still need to be evaluated. In fact, in society, the use of Piperaceae herbal extracts is more popular than a single preparation of piperine. People often use a combination of conventional medicines with herbal preparations in the hope of increasing the effects of drugs. For this reason, this study aimed to determine the potential for interactions between several Piperaceae herbal extracts when used together with drugs based on their *in vivo* pharmacological activity.

Materials and Methods

Materials

The sample materials were black pepper (*Piper nigrum* L.) powder, purchased from Materia Medica, Malang, and Javanese long pepper (*Piper retrofractum* Vahl.) obtained from Kalisat, Jember Regency. The samples were collected in August 2022 and were determined by Materia Medica Batu with the certificate number 074/599/102.20-A/2022. Piperine (Sigma-Aldrich), alprazolam (Mersi), diclofenac sodium (First Medipharma), and dexamethasone (Novapharin) tablets were also prepared. The chemicals used include 95% ethanol, hexane, ethyl acetate, aqua-dest, and sodium-CMC. Other consumables are capillary

tubes and TLC plates. The tools used were Rotarod (Ugo Basile), hotcold plate (Ugo Basile), plethysmometer (Ugo Basile), TLC-Densitometer, UV lamp, analytical balance (Ohaus), animal scales (Ohaus), and rat sonde.

Ethical approval and experimental animals

Ethical approval was obtained from the ethics committee of FKG-University of Jember, and a certificate of ethical approval number 1637/UN25.8/KEPK/DL/2022 was issued. The healthy Balb-c male mice, 6-8 weeks old and weighing 150-200 g body weight, were obtained. The animals were housed in plastic cages with free access to a normal diet and water. The rats were kept in a temperature-controlled room (22 ± 2 °C), with a 12 h light/dark cycle and relative humidity of 55 ± 10 %. They were acclimatised to the laboratory conditions for one week before the experiments. The ethics committee of FKG-University of Jember approved all experimental procedures. Ninety-six animals were used for the experiments.

Preparation and Extraction of plant materials

The Javanese long pepper was dried at room temperature, away from direct sunlight, for several days, then sorted and powdered. Previously, the Black pepper sample was purchased in powdered form. About 150 g of each Piperaceae powder was soaked with 1.5 L of 95% ethanol (1:10) with occasional stirring and then filtered. The marc was reextracted two times. The filtrate was evaporated using a rotary evaporator at 40°C and then dried in an oven at 50°C until a dry extract was obtained, coded BPE for Black pepper extract and JLPE for Javanese long pepper extract.

Determination of Piperine Levels

Each piperaceae extract was prepared at a 200 µg/mL concentration in 95% ethanol (p.a), whereas a standard piperine solution was prepared at 100 µg/mL. Analysis was performed using TLC-densitometry with 60 F254 silica gel TLC plates as a stationary phase and hexane-ethyl acetate $(1:1)$ as a mobile phase. $3 \mu L$ sample and standard piperine were spotted, then eluted with mobile phase until the spot appeared and was observed under a UV lamp λ 254 nm.

Drug–herbs interaction potency study through in vivo activity test

Thirty-two mice divided into eight groups consisting of negative control and seven treatment groups: (1) piperine (PIP) 20 mg/kg BW, (2) medicines (sodium diclofenac (DIC) 10 mg/kg BW or alprazolam (ALP) 1 mg/kg BW or dexamethasone (DEX) 3.2 mg/kg BW , (3) black pepper extract (BPE) 100 mg/kg BW, (4) Javanese long pepper extract $(JLPE)$ 125 mg/kg BW, (5) DIC/ALP/DEX+PIP, DIC/ALP/DEX+BPE, (7) DIC/ALP/DEX+JLPE.

Analgesic Activity Test

The test animals were placed on a hotplate at 55 ± 1 °C¹² to measure their basal latency time. Mice latency time not exceeding 15 seconds was used for the study, and treatment was given according to each group. The time between the mice being placed and the mice giving a response (licking or lifting their feet or jumping) was calculated as the latency time. The cut-off set was 15 seconds to prevent tissue damage. Latency time was measured periodically at 0, 0.5, 1, 1.5, 2, and 3 hours. The percentage of analgesic activity was determined at a peak time.¹³

Anxiolytic Activity Test

Motor coordination and balance were tested using mice Rotarod. Before testing, the mice were trained to stay on the Rotarod for at least 60 seconds a few days before regularly. The mice were placed on metal parts and ran at 40 rpm/minute. The time mice maintained balance by walking on a spin was measured periodically at 0 (basal), 60, 90, 120, and 180 minutes. At the peak time, the percentage of anxiolytic activity was calculated.¹⁴

Anti-inflammatory activity test

The mice's plantar basal volume was measured by dipping the sole in the plethysmometer. Mice were injected with 0.1 mL carrageenan intraplantar. Carrageenan 1% was prepared by mixing 100 mg powder in 1% sodium CMC suspension. Then, the plantar volume was measured at 0, 30, 60, 90, 120, 150, and 180 minutes after being treated. The oedema volume was calculated using the plantar volume at a specific time after carrageenan injection minus the volume before carrageenan injection. Then, each treatment's percentage of inflammation inhibitory activities was calculated after 3 hours.

Statistical analysis

The mice's oedema volume, latency, and endurance time were analysed with One Way ANOVA or Kruskal Wallis test with a confidence level of 95 %, followed by a post hoc test to determine differences between groups.

Results and Discussion

The extracts' yield obtained in this experiment was greatly improved by repeated maceration. The BPE and JLPE extract yields were 11.7% and 10.5%, respectively. This result still meets the requirements contained in the Herbal Pharmacopeia, which is 11.3% for black pepper and 8.3% for Javanese long pepper ethanol extract.

The piperine level in the extracts was determined by the standard regression equation y=241.9+9.445x. The result of the extract resolution using TLC plates is shown in Figure 1. The results showed PIP, BPE, and JLPE spots with the same RF value (0.64). The results showed the percentage of piperine content in BPE and JLPE, respectively, to be 20.46 ± 2.92 % and 15.65 ± 1.69 %.

Herbal Pharmacopoeia (2017) states that thick black pepper extract contains not less than 48.60% piperine, and in Javanese chilli extract, not less than 4.40%. Based on these references, the piperine content in BPE is much lower than the standard, whereas it is higher in JLPE. It may be due to various factors, including differences in growing places, which allow variations in their phytochemical components. The level of piperine found in BPE was higher than in JLPE. This was in line with the previous studies that showed that the highest piperine content of the entire piper genus was found in *Piper nigrum* L, with a range of 2-9%⁶, followed by *Piper colubrinum* (4.9%), *Piper longum* (3.7%), *Piper retrofractum* (2.3%), *Piper cubeba* (1.2%), and *Piper betle* (0.9%).⁴

The study also evaluated the *in vivo* effect of the drug–herbs interaction on the potency of analgesic activity of conventional medications. The result of the combination of Piperaceae herbs with diclofenac is shown in Figure 2. At 30 minutes post-treatment, the latency time of mice in all groups decreased, starting optimally at the first hour and reaching its peak at 1.5 hours, except for the BPE and JLPE, which peaked in the first hour. Studies have shown that the onset of diclofenac sodium is achieved within 60 minutes.¹⁵ Statistically, a significant difference in latency was only found at 60 and 90 minutes. According to the data in Table 1, at 60 minutes, the treatment group with DIC, both alone and in combination, began to show a similar effect marked by an increase in latency time. Meanwhile, the piperine and extract groups did not show a significant difference from the control, and no activity in 60 or 90 minutes was observed.

method. Piperine standart (A), BPE (B), JLPE (C).

The treatment with single DIC was not statistically significantly different from all combined DICs based on latency time. It was inconsistent with the existing theory that piperine has a pharmacokinetic interaction with drugs that are substrates of the drugmetabolising enzymes. Diclofenac sodium is absorbed fast through the GI tract, distributed, and eliminated quickly.¹⁶ In the body, diclofenac sodium is mainly converted to 4-hydroxy diclofenac by CYP2C9. Other metabolites, such as 5-hydroxy diclofenac and 3-hydroxy diclofenac, were mediated by CYP3A4.¹⁷ CYP2C9 is the primary enzyme responsible for NSAID metabolism, including diclofenac sodium.¹⁸ Meanwhile, the CYP3A4 enzyme is responsible for significant firstpass metabolism in diclofenac, causing low bioavailability of diclofenac (only about 60% reaches the systemic circulation).¹⁹ Piperine is known to inhibit CYP3A4 in humans²⁰ and is a selective competitive inhibitor of this enzyme, with an IC₅₀ value of $\langle 10 \mu M$. In addition, piperine also has potent inhibitory activity on CYP2C9 with an IC₅₀ value $\langle 100 \mu M$ ²¹. The metabolism of diclofenac, a substrate of CYP2C9 and CYP3A4 enzymes, can be inhibited, causing an increase in drug levels in the blood, which can also affect its effectiveness. Other *in vivo* studies have shown that combining piperine with glimepiride²² and warfarin²³ can change pharmacokinetic parameters and increase activity through CYP2C9 inhibition by piperine. A clinical study was conducted to determine piperine's effect on diclofenac's pharmacokinetics in healthy subjects. These studies showed that treatment with piperine could significantly increase Cmax, AUC, and t1/2 but decrease Kel and diclofenac clearance by inhibiting CYP2C9 enzymes.²⁴

In this study, the pharmacokinetic interactions that occurred were not followed by biological relevance, so an increase in diclofenac levels did not change the drug's activity. It occurs because diclofenac sodium metabolism does not only involve two enzymes (CYP2C9 and CYP3A4), but other metabolising enzymes are implicated. *In vitro* studies have shown that CYP2C8 also catalysed the 4-hydroxylation process. Diclofenac is converted to diclofenac glucuronide by UGT2B7, then to 4-hydroxy diclofenac glucuronide by CYP2C8, to be excreted in the urine and faeces. It explains the possibility of other pathways for eliminating diclofenac even though CYP2C9 and CYP3A4 have been inhibited.¹⁷

From Table 2, only the administration of BPE combined with DIC enhanced the effect of DIC. However, Piperaceae extract has complex constituents that can influence the effect. The variation in piperine levels coupled with the various phytochemical components contained in these plant extracts can also affect the effects, which can be seen from the differences in the latency time values and percentage of analgesic activity for each group.

The anxiolytic effects of the extracts are shown in Figure 3. The mice's endurance time decreased at 60 minutes, tended to last until 90 minutes, and increased at 120 and 180 minutes. The result was consistent with data on the onset of alprazolam, achieved within 20-60 minutes, with peak plasma concentrations reaching 1-2 hours. The survival time of mice on the Rotarod showed significant differences at each measurement time, starting from 60, 90, 120, and 180 minutes, based on the Kruskall-Wallis test (Table 3). At 60 minutes, there was a significant difference between the control and all treatment groups except JLPE. Likewise, in subsequent times, JLPE also did not significantly differ from the control group, which means that JLPE was the only extract that did not show anxiolytic activity. The group that was treated with ALP and BPE had similar profiles, which started to show anxiolytic effects at 60 minutes. However, as the average endurance time indicated, this activity decreased over time, similar to the control group at 120 minutes. Interestingly, it was found that the combination treatment had a significantly different endurance time and was much lower than the single administration of ALP, especially at 60 and 90 minutes. From Table 4, the anxiolytic activities of ALP combined with PIP, BPE, or JLPE were also higher than a single administration of ALP. Based on these results, PIP, BPE, and JLPE exhibited anxiolytic activity. In line with previous research, piperine has anxiolytic activity in stressed and non-stressed mice by inhibiting neuronal NOS.

Table 1: The mice's latency time at 60 and 90 minutes after various treatments

Groups	Latency time (second)		
	60^*	$90^{\rm #}$	
Control	6.4 ± 0.19^a	$6.6 \pm 0.29^{\rm a}$	
DIC	7.8 ± 0.27 ^{ab}	8.4 ± 0.14^b	
PIP	5.8 ± 0.39 ^{ac}	$6.4 \pm 0.63^{\circ}$	
BPE	6.0 ± 0.21 ^{ac}	$5.9 + 0.31$ ^a	
JLPE	7.6 ± 0.79 ^{ab}	$7.1 \pm 0.79^{\rm a}$	
$DIC + PIP$	7.6 ± 0.45^{ab}	8.3 ± 0.66^b	
$DIC + BPE$	8.1 ± 0.82^b	8.8 ± 0.56^b	
$DIC + ILPE$	7.6 ± 0.28 ^{ab}	$7.9 \pm 0.17^{\rm b}$	

Results are expressed as the mean \pm SEM (n=4 animals per group). The same superscript means no significant difference. p<0.05 were considered significant based on one-way ANOVA (*), followed by LSD and Kruskall-Wallis, followed by the Mann-Whitney (#) test.

Figure 2: Effects of various treatments on mice latency time. Results are expressed as the mean \pm SEM (n=4 animals per group). $p<0.05$ were considered significant based on one-way ANOVA (*) and the Kruskall-Wallis test.

Figure 3: Effects of various treatments on mice endurance time. Results are expressed as the mean \pm SEM (n=4 animals per group). $p<0.05$ were considered significant based on the Kruskall-Wallis test (*).

However, it only increased GABA levels in mice without stress.²⁵ Administration of pepper fruit methanol extract to Alzheimer's mice model showed anxiolytic activity through the Elevated Plus-Maze $(EPM)^{26}$ and forced swimming test,²⁷ as well as the essential pepper oil. It also exhibited anxiolytic activity through the involvement of 5-HT1A receptors.²⁸ The combination with PIP, BPE, or JLPE also enhanced the activity of alprazolam. Despite the suggestion that piperine and BPE are known to have similar activity as previously described, this finding may also be related to the presence of pharmacokinetic interactions between piperine and alprazolam, especially in the metabolic phase. Alprazolam is converted into two primary metabolites, namely 4-hydroxy alprazolam and α-hydroxy alprazolam, through CYP3A4 enzymes.² This enzyme inhibition increases alprazolam blood levels and enhances its effect. However, there has been no research on the interaction between alprazolam and piperine. Other similar studies have proven a pharmacokinetic interaction between piperine and other drugs as substrates of CYP3A4, including midazolam³⁰ and carbamazepine.³¹ Based on these studies, piperine can increase bioavailability and halflife but decrease the constant clearance and elimination of the two drugs. The increased effect of ALP due to the interaction with PIP was also shown in combination with BPE and JLPE. The possible reason could be that piperine, the main phytochemical compound in the Piperaceae family, occurs in a large amount in black pepper and Javanese long pepper.⁶ However, the other phytochemicals in these two plants could also influence their activity, although this may not be as significant as the combination with piperine.

The results of anti-inflammation activity are shown in Figure 4 and Table 5. As observed, the combination treatment of DEX+PIP/BPE/JLPE reduced the oedema volume of carrageenaninduced mice better than dexamethasone alone, especially at 150 and 180 minutes. The body metabolises dexamethasone to 6α-hydroxy dexamethasone and 6 β -hydroxy dexamethasone by the CYP3A4 enzyme.³² As previously explained, the inhibition of this enzyme by piperine produces an increase in dexamethasone levels in the blood, so the effect will also increase. In line with this theory, Table 6 shows that combining PIP, BPE, or JLPE with ALP can increase the inflammation inhibitory activity. Interestingly, this study showed a change in onset from 60 to 30 minutes in the combined DEX+PIP/BPE/JLPE treatments. Reports have shown that dexamethasone reaches peak blood levels within 1 hour.³³ The shift in Tmax is presumable not only due to the inhibition of metabolising enzymes but also due to the inhibition of the P-glycoprotein (Pgp) by piperine. Pgp is a member of the ATP binding cassette (ABC) transporter superfamily, which plays a role in drug transport. In the intestine, Pgp pumps the drug back into the lumen, which causes a decrease in absorption. Apart from enterocytes, Pgp is also expressed in hepatocytes, contributing to first-pass metabolism.³⁴ Piperine had vigorous Pgp inhibitory activity on the transport of several drugs *in vitro* with an \overline{IC}_{50} value < 100 μ M. Pgp inhibition has been shown to affect the pharmacokinetics of several drugs, such as

fexofenadine¹⁰ and domperidone,¹¹ substrates of Pgp. Dexamethasone itself is one of the physiological substrates of PgP.³⁵ Inhibition of these transporters by piperine can increase the bioavailability and absorption of the drug. This explanation may cause a shift in the Tmax of DEX when given together with PIP or Piperaceae extracts, as shown in this study.

Table 2: Percentage of analgesic activity after various treatments

Groups	Analgesic activitiy (%)
DIC	21.73
PIP	-2.68
BPE	-8.63
JLPE	5.65
$DIC+PIP$	20.24
$DIC+BPE$	25.60
$DIC+JLPE$	15.18

Figure 4: Effects of various treatments on mice oedema volume per unit time. Results are expressed as the mean \pm SEM (n=4 animals per group). *p*<0.05 were considered significant based on the Kruskall-Wallis test (*).

	Endurance time (second)				
Groups	60	90	120	180	
Control	$56 \pm 4.0^{\rm a}$	$60 \pm 0.0^{\rm a}$	$60 \pm 0^{\rm a}$	$60 \pm 0.0^{\rm a}$	
ALP	30 ± 5.6^b	$21 \pm 9.4^{\rm b}$	31 ± 11.8^b	$50 \pm 10.5^{\rm a}$	
PIP	$31 \pm 6.5^{\rm b}$	45 ± 11.3^{ab}	42 ± 10.8 ^{ab}	$51 \pm 8.8^{\rm a}$	
BPE	21 ± 4.3^b	$20 \pm 6.6^{\rm b}$	22 ± 7.2^b	30 ± 11.9 ^{ab}	
JLPE	$53 \pm 7.0^{\rm a}$	$53 \pm 7.5^{\rm a}$	55 ± 5.0^{ab}	$60 \pm 0.0^{\rm a}$	
$AI.P+PIP$	$6 \pm 1.5^{\circ}$	3 ± 1 ^c	$3 \pm 0.8^{\text{cb}}$	$12 \pm 3.5^{\rm b}$	
$AI.P+BPE$	12 ± 2.4 ^{cd}	9 ± 3.9^{bc}	$25 + 12.5^b$	$43 \pm 10.5^{\rm a}$	
$AI.P+JLPE$	21 ± 3.3^{bd}	$12 \pm 1.4^{\rm bc}$	$21 \pm 5.5^{\rm b}$	$35 + 8.5^{ab}$	

Table 3: The mice's endurance time on Rotarod at 60, 90, 120, and 180 minutes after various treatments

Results are expressed as the mean \pm SEM (n=4 animals per group). The same superscript showed no significant difference. p<0.05 were considered significant based on Kruskall-Wallis, followed by the Mann-Whitney test.

ISSN 2616-0692 (Electronic)

Table 4: Percentage of anxiolytic activity after various treatments

Conclusion

This study concluded that black pepper or Javanese long pepper extract containing piperine or piperine alone has potential drug interactions, especially with diclofenac sodium, alprazolam, and dexamethasone. The study results highlighted that these interactions may be beneficial

because they can increase the drug's pharmacological activity. Further research is needed for its toxicity and pharmacokinetic profile to ensure the safety of these drug interactions. The results of this study provide a formal reference for persons who may use a combination of Piperaceae herbal preparations and conventional medicines.

Conflict of Interest

The authors declare no conflict of interest.

Authors' Declaration

The authors hereby declare that the work presented in this article is original and that any liability for claims relating to the content of this article will be borne by them.

Acknowledgements

The author's thanks go to the University of Jember through the Unej Research and Community Service Institute (LP2M) for the funds provided through the Keris-Dimas Research Grant program.

Results are expressed as the mean \pm SEM (n=4 animals per group). The same superscript showed no significant difference. $p<0.05$ were considered significant based on Kruskall-Wallis, followed by the Mann-Whitney test.

References

- 1. Borse SP, Singh DP, Nivsarkar M. Understanding the relevance of herb–drug interaction studies with special focus on interplays: a prerequisite for integrative medicine. Porto Biomed J. 2019;4(2):e15. doi:10.1016/j.pbj.0000000000000015
- Pane MH, Rahman AO, Ayudia EI. Overview of the Use of Herbal Medicines in Indonesian Society and Their Interactions with Conventional Medicines in 2020. J Med Stud. 2021;1(1):40-62.
- Hikmah, A SD. The relationship of piperaceae based on morphological character of vegetative organ in Meru Betiri National Park Jember East Java. In: The Second International Conference on Life Sciences and Biotechnology (ICOLIB). ; 2017:222-226.
- 4. Martha Perez Gutierrez R, Maria Neira Gonzalez A, Hoyo-Vadillo C. Alkaloids from Piper: A Review of its Phytochemistry and Pharmacology. Mini Rev Med Chem. 2013;13(2):163-193. doi:10.2174/138955713804805148
- 5. Tiwari A, Mahadik KR, Gabhe SY. Piperine: A comprehensive review of methods of isolation, purification, and biological properties. Med Drug Discov. 2020;7:100027. doi:10.1016/j.medidd.2020.100027
- 6. Stojanović-Radić Z, Pejčić M, Dimitrijević M, Aleksic A, Kumar NVA, Salehi B, Cho WC, Sharifi-Rad J. Piperine-A Major Principle of Black Pepper: A review of its bioactivity and studies. Appl Sci. 2019;9(20):1-29. doi:10.3390/app9204270
- 7. Meghwal M, Goswami TK. *Piper nigrum* and piperine: An update. Phyther Res. 2013:27(8):1121-1130. doi:10.1002/ptr.4972
- 8. Bano G, Raina RK, Zutshi U, Bedi KL, Johri RK, Sharma SC. Effect of piperine on bioavailability and pharmacokinetics of propranolol and theophylline in healthy volunteers. Eur J Clin Pharmacol. 1991;41(6):615-617. doi:10.1007/BF00314996
- 9. Shoba G, Joy D, Joseph T, Majeed M, Rajendran R, Srinivas PSSR. Influence of piperine on the pharmacokinetics of

curcumin in animals and human volunteers. Planta Med. 1998;64(4):353-356. doi:10.1055/S-2006-957450

- 10. Bedada SK, Boga PK. The influence of piperine on the pharmacokinetics of fexofenadine, a P-glycoprotein substrate, in healthy volunteers. Eur J Clin Pharmacol. 2017;73(3):343-349. doi:10.1007/S00228-016-2173- 3/FIGURES/1
- 11. Kolakota R, Bothsa A, Mugada V. Impact of N-acyl piperidine (Piperine) from *Piper nigrum* on the pharmacokinetics of CYP3A substrate almotriptan in rats. Trop J Nat Prod Res. 2020;4(8):378-384. doi:10.26538/tjnpr/v4i8.10
- 12. Abdullahi ID, Yaro AH, Nazifi AB. Preliminary studies on the anti-inflammatory and analgesic effects of methanol leaf extract of *Ficus asperifolia* Miq. Trop J Nat Prod Res. 2020;4(3):85-90. doi:10.26538/tjnpr/v4i3.5
- 13. Shivananda A, Muralidhara Rao D, Jayaveera KN. Analgesic and anti-inflammatory activities of *Citrus maxima* (J.Burm.) Merr. in animal models. Res J Pharm Biol Chem Sci. 2013;4(2):1800-1810.
- 14. Mishra PS, Phadnis P, Vyas S, Nyati P. Study of CNS activities of piperine Perse and its bio-enhancing effect on various drugs in experimental animal models. Int J Pharm Pharm Sci. 2016;8(4):135-140.
- 15. Diener HC, Montagna P, Gács G, Lyczak P, Schumann G, Zöller B, Mulder LJMM, Siegel J, Edson K. Efficacy and tolerability of diclofenac potassium sachets in migraine: A randomised, double-blind, cross-over study in comparison with diclofenac potassium tablets and placebo. Cephalalgia. 2006;26(5):537-547. doi:10.1111/j.1468- 2982.2005.01064.x
- 16. Yuan J, Ma H, Cen N, Zhou A, Tao H. A pharmacokinetic study of diclofenac sodium in rats. Biomed Reports. 2017;7(2):179-182. doi:10.3892/br.2017.942
- 17. Tang W. The Metabolism of Diclofenac Enzymology and Toxicology Perspectives. Curr Drug Metab. 2005;4(4):319- 329. doi:10.2174/1389200033489398
- 18. Zi J, Liu D, Ma P, Huang H, Zhu J, Wei D, Yang J, Chen C. Effects of CYP2C9*3 and CYP2C9*13 on diclofenac metabolism and inhibition-based drug-drug interactions. Drug Metab Pharmacokinet. 2010;25(4):343-350. doi:10.2133/dmpk.DMPK-10-RG-009
- 19. Todd PA, Sorkin EM. Diclofenac sodium. A reappraisal of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy. Drugs. 1988;35(3):244-285. doi:10.2165/00003495-198835030-00004
- 20. Bhardwaj RK, Glaeser H, Becquemont L, Klotz U, Gupta SK, Fromm MF. Piperine, a major constituent of black pepper, inhibits human P-glycoprotein and CYP3A4. J Pharmacol Exp Ther. $2002;302(2):645-650$. doi:10.1124/jpet.102.034728
- 21. Shamsi S, Tran H, Tan RSJ, Tan ZJ, Lim LY. Curcumin, Piperine, and Capsaicin: A Comparative Study of Spice-Mediated Inhibition of Human Cytochrome P450 Isozyme Activities. Drug Metab Dispos. 2017;45(1):49 LP - 55. doi:10.1124/dmd.116.073213
- 22. Veeresha C, Sujath S, Rani TS. Effect of piperine on the pharmacokinetics and pharmacodynamics of glimepiride in normal and streptozotocin - Induced diabetic rats. Nat Prod Commun. 2012;7(10):1283-1286. doi:10.1177/1934578x1200701009
- 23. Zayed A, Babaresh WM, Darweesh RS, El-Elimat T, Hawamdeh SS. Piperine alters the pharmacokinetics and

anticoagulation of warfarin in rats. J Exp Pharmacol. 2020;12:169-179. doi:10.2147/JEP.S257919

- 24. Bedada SK, Boga PK. The influence of piperine on the pharmacokinetics of fexofenadine, a P-glycoprotein substrate, in healthy volunteers. Eur J Clin Pharmacol. 2017;73(3):343-349. doi:10.1007/S00228-016-2173-3
- 25. Gilhotra N, Dhingra D. Possible involvement of GABAergic and nitriergic systems for antianxiety-like activity of piperine in unstressed and stressed mice. Pharmacol Rep. 2014;66(5):885-891. doi:10.1016/j.pharep.2014.05.008
- 26. Emon NU, Kaiser M, Islam M, Kabir MFI, Uddin MJ, Jyoti MA, Tanjil SM, Rasel ANM, Alam S, Islam MN. Anxiolytic and thrombolytic investigation of methanol extract of *Piper nigrum* L. Fruits and *Sesamum indicum* L. seeds. J Adv $2020;3(3):158-164.$ doi:10.5455/jabet.2020.d121
- 27. Hritcu L, Noumedem JA, Cioanca O, Hancianu M, Postu P, Mihasan M. Anxiolytic and antidepressant profile of the methanolic extract of *Piper nigrum* fruits in beta-amyloid (1- 42) rat model of Alzheimer's disease. Behav Brain Funct. 2015;11(1):1-13. doi:10.1186/s12993-015-0059-7
- 28. Ghosh S, Kumar A, Sachan N, Chandra P. Anxiolytic and antidepressant-like effects of essential oil from the fruits of *Piper nigrum* Linn. (Black pepper) in mice: involvement of serotonergic but not GABAergic transmission system. Heliyon. 2021;7(4):e06884. doi:10.1016/j.heliyon.2021.e06884
- 29. Pai H V, Upadhya SC, Chinta SJ, Hegde SN, Ravindranath V. Differential metabolism of alprazolam by liver and brain cytochrome (P4503A) to pharmacologically active metabolite. Pharmacogenomics J. 2002;2(4):243-258. doi:10.1038/sj.tpj.6500115
- 30. Rezaee MM, Kazemi S, Kazemi MT, Gharooee S, Yazdani E, Gharooee H, Shiran MR, Moghadamnia AA.The effect of piperine on midazolam plasma concentration in healthy volunteers, a research on the CYP3A-involving metabolism. DARU, J Pharm Sci. 2014;22(1):1-7. doi:10.1186/2008- 2231-22-8
- 31. Pattanaik S, Hota D, Prabhakar S, Kharbanda P, Pandhi P. Pharmacokinetic interaction of single dose of piperine with steady-state carbamazepine in epilepsy patients. Phytother Res. 2009;23(9):1281-1286. doi:10.1002/ptr.2676
- 32. Berlińska A, Świątkowska-Stodulska R, Sworczak K. Factors Affecting Dexamethasone Suppression Test Results. Exp Clin Endocrinol Diabetes. 2020;128(10):667-671. doi:10.1055/a-1017-3217
- 33. Riaz M, Akram M, Egbuna C, Ifemeje J, Chikwendu J, Patrick-Iwuanyanwu K, Olatunde A, Tijjani H, Adetunji C, Shivamallu C, Olisah M, Uche C. Dexamethasone. Coronavirus Drug Discov Vol 1 SARS-CoV-2 Prev Diagnosis, Treat. Published online, 2022:169-179. doi:10.1016/B978-0-323-85156-5.00028-6
- 34. Finch A, Pillans P. P-glycoprotein and its role in drug-drug interactions. Aust Prescr. 2014;37(4):137-139. doi:10.18773/AUSTPRESCR.2014.050
- 35. Athukuri BL, Neerati P. Enhanced oral bioavailability of domperidone with piperine in male Wistar rats: Involvement of CYP3A1 and P-gp inhibition. J Pharm Pharm Sci. 2017;20(1):28-37. doi:10.18433/j3mk72
- 36. Ueda K, Okamura N, Hirai M, et al. Human P-glycoprotein transports cortisol, aldosterone, and dexamethasone but not progesterone. J Biol Chem. 1992;267(34):24248-24252. doi:10.1016/S0021-9258(18)35757-0